All HHS Contracts — May 14, 2026

Pfizer's definitive cost-no-fee contract (base + $25M options totaling $93M ceiling) for biotechnology R&D (NAICS 541711) could see option exercises, though only $18.7M has been outlayed since 2015.

Just 27% ($18,678,022) outlayed over ~10 years on the $68M obligation signals low execution pace ahead of the September 30, 2025 performance end.

Pfizer Inc's HHS/BARDA contract nears end (Sep 30, 2025) with only $18.7M outlayed of $68M obligated and $25M options unexercised, risking lapse without renewal.

Cost-no-fee structure on Pfizer's $68M HHS contract reimburses costs without fee, exposing to budget scrutiny given ~$1.87M annual outlay average.

Pfizer Inc holds $25M unexercised options on existing HHS/BARDA $68M biotech R&D contract (PSC AN13) under full and open competition.

Pfizer Inc's $68M obligation (only $18.7M outlayed since 2015) exemplifies BARDA's long-duration (10-year) health R&D commitments under full and open competition.

{"entity"=>"Pfizer Inc", "reason"=>"$68M HHS/BARDA contract with $18.7M outlayed to date and $25M options pending amid 2025 end date.", "trigger"=>"Option exercise; outlay acceleration; contract completion Sep 30, 2025"}

{"entity"=>"Biotechnology sector", "reason"=>"HHS/BARDA's neutral signal (3/10 strength) on Pfizer's $68M R&D award highlights slow-paced civilian biotech funding.", "trigger"=>"HHS budget announcements for BARDA priorities"}